Page last updated: 2024-09-05

sch 58261 and Parkinsonian Disorders

sch 58261 has been researched along with Parkinsonian Disorders in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, L; Engber, T; Grant, D; Hetu, G; Huang, C; Jin, X; Kumaravel, G; Peng, B; Petter, RC; Phadke, D; Reilly, J; Smits, G; Tam, S; Vu, CB; Zhang, J	1

Other Studies

1 other study(ies) available for sch 58261 and Parkinsonian Disorders

Article	Year
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists. Journal of medicinal chemistry, 2004, Aug-12, Volume: 47, Issue:17 Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Biological Availability; Brain; Catalepsy; Heterocyclic Compounds, 2-Ring; In Vitro Techniques; Male; Mice; Parkinsonian Disorders; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Structure-Activity Relationship; Triazines; Triazoles	2004

Article

Year

Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.

Journal of medicinal chemistry, 2004, Aug-12, Volume: 47, Issue:17

Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Biological Availability; Brain; Catalepsy; Heterocyclic Compounds, 2-Ring; In Vitro Techniques; Male; Mice; Parkinsonian Disorders; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Structure-Activity Relationship; Triazines; Triazoles

2004